HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

Abstract Approximately a half of breast tumors classified as HER2-negative exhibit HER2-low-positive expression. We recently described a high instability of HER2-low-positive expression from primary breast cancer (BC) to relapse. Previous studies reporting discordance in HER2 status between baseline...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, Francesca Porra, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Portfolio 2022-05-01
Colección:npj Breast Cancer
Acceso en línea:https://doi.org/10.1038/s41523-022-00434-w
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares